Flucelvax QIV

Flucelvax QIV is a cell-culture-derived quadrivalent inactivated subunit influenza vaccine developed by Seqirus (a CSL company). Unlike traditional influenza vaccines produced in embryonated chicken eggs, Flucelvax QIV is manufactured using Madin-Darby Canine Kidney (MDCK) cells. This cell-based production method avoids egg-adaptive mutations that can occur during viral propagation in eggs, potentially leading to a closer match between the vaccine antigens and circulating wild-type viruses. The vaccine contains purified haemagglutinin (HA) antigens from four influenza virus strains (two influenza A subtypes and two influenza B lineages) as recommended by the World Health Organization. It is indicated for the prevention of seasonal influenza in adults and children. Clinical evaluations, such as the ComFluCOV trial, have also assessed its safety and immunogenicity when co-administered with COVID-19 vaccines.

Brand names

Flucelvax QIVFlucelvax TetraFlucelvax Quadrivalent

Other names

QIVccell-based quadrivalent inactivated influenza virus vaccine